Sequenom, Inc.
 (SQNM)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Apr. 19, 2012, 10:29 AM

    Shares of Sequenom (SQNM +6.9%) jump higher in early trading after the firm announces an expanded agreement with healthcare cost management firm Provider Multiplan to include the MaterniT21 fetal test at more than 900 providers in its network. The frothy bid for Human Genome is also adding to the bullish sentiment over Sequenom - viewed as a juicy takeover candidate itself.

    | Apr. 19, 2012, 10:29 AM
  • Apr. 16, 2012, 11:34 AM

    Shares of Sequenom (SQNM +9.5%) pop after the firm raises its estimate for billings for MaterniT21 in 2012 to 40K from a previous forecast of 25K. The firm says it will increase internal production goals based on the improved outlook.

    | Apr. 16, 2012, 11:34 AM
  • Apr. 16, 2012, 9:05 AM

    Premarket gainers: ECYT +114%. DRJ +30%. CSIQ +9%. SQNM +9%. LDK +7%. TSL +6%. RENN +4%. YGE +4%. STX +4%. JASO +4%. STP +4%. ANR +3%.
    Losers: PCO -47%. HALO -22%. SANG -5%. BAX -4%. MAT -4%. RBS -3%. VALE -3%.

    | Apr. 16, 2012, 9:05 AM
  • Mar. 8, 2012, 9:00 AM

    Premarket gainers: MWA +18%. XOMA +8%. SQNM +7%. NBG +5%. GNOM +4%. CCI +4%. RAD +5%. MWW +4%. DB +4%. ING +4%. RIO +3%. MT +3%. BUD +3%. DRYS +3%. ARMH +3%. STO +3%. UBS +3%. SINA +3%. AEO +3%.
    Losers: DNDN -13%. STP -6%. ALKS -5%. WSM -4%. AMLN -4%. MCD -3%. CIGX -3%. UAL -3%. AGNC -3%.

    | Mar. 8, 2012, 9:00 AM | 2 Comments
  • Mar. 7, 2012, 4:47 PM
    Sequenom (SQNM): Q4 EPS of -$0.22 misses by $0.04. Revenue of $15.5M (+12.3% Y/Y) in-line. Shares +6.3% AH. (PR)
    | Mar. 7, 2012, 4:47 PM
  • Feb. 21, 2012, 11:26 AM
    Time Magazine is slated to print a feature in its Feb. 27th edition that profiles the possible benefits of Sequenom's (SQNM +0.2%) new product for testing a prenatal baby's DNA for Down syndrome. (sneak peek .pdf)
    | Feb. 21, 2012, 11:26 AM
  • Jan. 25, 2012, 10:02 AM

    The hostile bid from Roche to take over Illumina spills over to more names (previous: PACB, GNOM, LIFE) on M&A speculation - as Sequenom (SQNM +2.2%), Qiagen (QGEN +1.5%), and Luminex (LMNX +1.1%) all catch bids in early trading.

    | Jan. 25, 2012, 10:02 AM
  • Jan. 20, 2012, 10:57 AM

    Sequenom (SQNM -3.5%) bounces back a bit after being down over 8% just prior to the opening bell, in reaction to the company's pricing of its 13M share offering at $4.15 - a 10% discount to yesterday's close.

    | Jan. 20, 2012, 10:57 AM
  • Jan. 20, 2012, 9:15 AM

    Premarket gainers: INSM +24%. ASIA +16%. SWKS +6%. URRE +6%. MPC +5%. BCS +4%. CTIC +4%. RBS +3%. IBM +3%. SAVE +3%. MSFT +3%.
    Losers: ALTH -20%. GOOG -8%. AONE -7%. SQNM -6%. HTGC -6%. COF -6%. PH -5%. ZIOP -5%. MMLP -5%. BWP -4%. CX -4%. CUK -4%. ARCC -4%. CCL -3%. NVS -3%. MT -3%.

    | Jan. 20, 2012, 9:15 AM
  • Jan. 19, 2012, 4:11 PM

    Shares of Sequenom (SQNM) fall 7.8% AH after the firm announces that it plans to sell shares in an underwritten public offering without specifying an amount or a time period.

    | Jan. 19, 2012, 4:11 PM
  • Dec. 19, 2011, 9:10 AM

    Premarket gainers: WINN +72%. SQNM +7%. AMR +5%. TTM +4%. CVC +4%. CPST +3%.
    Losers: MAS -6%. SCHN -6%. EGO -6%. LPL -6%. SNV -4%. LYG -3%.

    | Dec. 19, 2011, 9:10 AM
  • Dec. 19, 2011, 8:01 AM

    Sequenom (SQNM) rises 4% after announcing "numerous leading healthcare providers" in the U.S. have begun ordering its MaterniT21 product, which is used to analyze a baby's DNA during pregnancy for signs of Down Syndrome. Ed Pullen believes the nature of Sequenom's product "raises huge questions" about its usage. (previously)

    | Dec. 19, 2011, 8:01 AM | 1 Comment
  • Nov. 23, 2011, 11:02 AM

    Sequenom (SQNM -5.3%) sells off after filing for a $150M mixed shelf offering consisting of common stock, preferred stock, debt, and warrants. The maker of DNA analysis products says it plans to use the proceeds for "general corporate purposes."

    | Nov. 23, 2011, 11:02 AM | 2 Comments
  • Oct. 17, 2011, 10:38 AM

    Shares of Sequenom (SQNM +11.1%) pop after the company announces the launch of its MaterniT21 noninvasive prematernal test for Down syndrome. The test is now available in 20 metropolitan cities for expectant women.

    | Oct. 17, 2011, 10:38 AM
  • May 9, 2011, 9:00 AM

    Premarket gainers: INO +13%. DTG +9%. BSFT +8%. AFFX +7%. ALKS +6%. EXK +5%. GPL +5%. SYY +5%. ELN +4%. HL +4%. SQNM +3%. CEF +3%. SD +3%.
    Losers: ZSL -11%. ZRAN -10%. GKK -8%. IRE -3%. LEXG -3%.

    | May 9, 2011, 9:00 AM
  • Dec. 2, 2010, 9:00 AM

    Premarket gainers: WBD +30%. RNN +22%. PSS +16%. ANF +8%. WTSLA +8%. S +8%. FNSR +6%. SGMO +5%. STP +4%.
    Losers: SQNM -9%. ARO -9%. SEP -4%. AEO -4%.

    | Dec. 2, 2010, 9:00 AM
Company Description
Sequenom Inc is a molecular diagnostic testing and genetics analysis company which provides molecular diagnostic testing services.
Sector: Healthcare
Industry: Biotechnology
Country: United States